2025

• Tremblay SA, Nathan Spreng R, Wearn A, Alasmar Z, Pirhadi A, Tardif CL, Chakravarty MM, Villeneuve S, Leppert IR, Carbonell F, Medina YI, Steele CJ, Gauthier CJ; PREVENT-AD Research Group.
  Sex and APOE4-specific links between cardiometabolic risk factors and white matter alterations in individuals with a family history of Alzheimer’s disease.
  Neurobiol Aging. 2025 Mar 8;150:80-96. Epub ahead of print. [full text]
• Tremblay C, Rahayel S, Pastor-Bernier A, St-Onge F, Vo A, Rheault F, Daneault V, Morys F, Rajah N, Villeneuve S, Dagher A; PREVENT-AD Research Group; ADNI.
  Uncovering atrophy progression pattern and mechanisms in individuals at risk of Alzheimer’s disease.
  Brain Commun. 2025 Mar 4;7(2):fcaf099. [full text]
• Walker CS, Noriega de la Colina AE, Li L, Boulanger C, Thovinakere N, Noly-Gandon A, Barnoin G, Bennett M, Caplan J, Côté L, Elbaz S, Bao SFK, Kara R, Lavoie N, Nguyen M, Otaner F, Pallett-Wiesel H, Piché JV, Powers A, Ricciardelli S, Williams K, Déry C, Tremblay-Mercier J, Poirier J, Villeneuve S, Kramer AF, Geddes MR; PREVENT-AD Research Group.
  Protocol for an intergenerational randomized controlled trial to enhance physical activity in older adults at risk for Alzheimer’s disease.
  J Prev Alzheimers Dis. 2025 Mar;12(3):100039. [full text]
• Yakoub Y, Gonzalez-Ortiz F, Ashton NJ, Déry C, Strikwerda-Brown C, St-Onge F, Ourry V, Schöll M, Geddes MR, Ducharme S, Montembeault M, Rosa-Neto P, Soucy JP, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; PREVENT-AD Research Group.
  Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window.
  Alzheimers Dement. 2025 Feb;21(2):e14537. [full text]
• Metz A, Zeighami Y, Ducharme S, Villeneuve S, Dadar M.
  Frontotemporal dementia subtyping using machine learning, multivariate statistics and neuroimaging.
  Brain Commun. 2025 Feb 11;7(1):fcaf065. [full text]
• Bussy A, Patel R, Parent O, Salaciak A, Bedford SA, Farzin S, Tullo S, Picard C, Villeneuve S, Poirier J, Breitner JC, Devenyi GA; PREVENT-AD Research Group; Tardif CL, Chakravarty MM.
  Exploring morphological and microstructural signatures across the Alzheimer’s spectrum and risk factors.
  Neurobiol Aging. 2025 Feb 7;149:1-18. Epub ahead of print. [abstract]
• Fischer L, Molloy EN, Pichet Binette A, Vockert N, Marquardt J, Pacha Pilar A, Kreissl MC, Remz J, Tremblay-Mercier J, Poirier J, Rajah MN, Villeneuve S; PREVENT-AD Research Group; Maass A.
  Precuneus activity during retrieval is positively associated with amyloid burden in cognitively normal older APOE4 carriers.
  J Neurosci. 2025 Feb 5;45(6):e1408242024. [full text]
• Wiels WA, Oomens JE, Engelborghs S,… Villeneuve S,… Vos SJB, Visser PJ, Jansen WJ, and the Amyloid Biomarker Study group; for ADNI, A4 Study group, DIAN, EPAD consortium, FACEHBI, HABS, Japanese ADNI, KBASE, PREVENT-AD research group
  Depressive symptoms and amyloid pathology.
  JAMA Psychiatry. 2025 Jan 22. Epub ahead of print. [abstract]
• Ao J, Picard C, Auld D, Zetterberg H, Brinkmalm A, Blennow K, Villeneuve S, Breitner JCS, Poirier J; PREVENT-AD research group.
  Novel synaptic markers predict early tau pathology and cognitive deficit in an asymptomatic population at risk of Alzheimer’s disease.
  Mol Psychiatry. 2025 Jan 18. Epub ahead of print. [abstract]

2024

• Gallego-Rudolf J, Wiesman AI, Pichet Binette A, Villeneuve S, Baillet S; PREVENT-AD Research Group.
  Synergistic association of Aβ and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults.
  Nat Neurosci. 2024 Nov;27(11):2130-2137. Epub 2024 Sep 18. [full text]
• Meilleur-Durand S, Lévesque M, St-Onge F, Masellis M, Hsiung GR, Jarrett P, Villeneuve S, Léger G, Salmon D, Galasko D, Cunnane SC, Gauthier S, Callahan B, Sellami L, Hudon C, Macoir J, Verret L, Cassivi-Joncas A, Comishen M, Laforce R Jr.
  Multicenter validation of the English version of the dépistage cognitif de Québec: a cognitive screening tool for atypical dementias.
  Arch Clin Neuropsychol. 2024 Oct 11:acae092. Epub ahead of print. [full text]
• Wen J, Yang Z, Nasrallah IM,… Villeneuve S,… Shen L, Shou H, Davatzikos C.
  Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimer’s disease continuum.
  Transl Psychiatry. 2024 Oct 5;14(1):42. [full text]
• Yang Z, Wen J, Erus G,… Villeneuve S,… Shou H, Nasrallah IM, Davatzikos C.
  Brain aging patterns in a large and diverse cohort of 49,482 individuals.
  Nat Med. 2024 Oct;30(10):3015-3026. Epub 2024 Aug 15. [abstract]
• Quesnel MJ, Labonté A, Picard C, Bowie DC, Zetterberg H, Blennow K, Brinkmalm A, Villeneuve S, Poirier J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT‐AD Research Group.
  Osteopontin: A novel marker of pre-symptomatic sporadic Alzheimer’s disease.
  Alzheimers Dement. 2024 Sep;20(9):6008-6031. Epub 2024 Jul 28. [full text]
• Wiesman AI, Gallego-Rudolf J, Villeneuve S, Baillet S, Wilson TW; PREVENT‐AD Research Group.
  Neurochemical organization of cortical proteinopathy and neurophysiology along the Alzheimer’s disease continuum.
  Alzheimers Dement. 2024 Sep;20(9):6316-6331. Epub 2024 Jul 12. [full text]
• Wearn A, Tremblay SA, Tardif CL, Leppert IR, Gauthier CJ, Baracchini G, Hughes C, Hewan P, Tremblay-Mercier J, Rosa-Neto P, Poirier J, Villeneuve S, Schmitz TW, Turner GR, Spreng RN; PREVENT-AD Research Group.
  Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status.
  Nat Commun. 2024 Jun 3;15(1):4706. [full text]
• Turner GR, Hewan P, Wearn A, van Dooren R, Wyatt L, Leppert IR, Baracchini G, Hughes C, Williams KM, Sylvain E, Tremblay-Mercier J, Poirier J, Villeneuve S, Tardif C, Spreng RN; PREVENT-AD Research Group.
  Locus coeruleus integrity is related to an exploitation-based decision-making bias in older adulthood.
  Proc Natl Acad Sci USA. 2024 May 28;121(22):e2322617121. [full text]
• Qiu T, Liu ZQ, Rheault F, Legarreta JH, Valcourt Caron A, St-Onge F, Strikwerda-Brown C, Metz A, Dadar M, Soucy JP, Pichet Binette A, Spreng RN, Descoteaux M, Villeneuve S; PREVENT‐AD Research Group.
  Structural white matter properties and cognitive resilience to tau pathology.
  Alzheimers Dement. 2024 May;20(5):3364-3377. Epub 2024 Apr 1.[full text]
• Dauar MT, Picard C, Labonté A, Breitner J, Rosa-Neto P, Villeneuve S, Poirier J; PREVENT-AD Research Group.
  Contactin 5 and apolipoproteins interplay in Alzheimer’s disease.
  J Alzheimers Dis. 2024 Apr 7;98(4):1361-1375. [abstract]
• Baril AA, Picard C, Labonté A, Sanchez E, Duclos C, Mohammediyan B, Breitner JCS, Villeneuve S, Poirier J; PREVENT-AD Research Group.
  Longer sleep duration and neuroinflammation in at-risk elderly with a parental history of Alzheimer’s disease.
  Sleep. 2024 Mar 25:zsae081. Epub ahead of print. [full text]
• Zhou J, Wearn A, Huck J, Hughes C, Baracchini G, Tremblay-Mercier J, Poirier J, Villeneuve S, Tardif CL, Chakravarty MM, Daugherty AM, Gauthier CJ, Turner GR, Spreng RN; PREVENT-AD Research Group.
  Iron deposition and distribution across the hippocampus is associated with pattern separation and pattern completion in older adults at risk for Alzheimer’s disease.
  J Neurosci. 2024 Feb 22:e1973232024. Epub ahead of print. [abstract]
• Baril AA, Picard C, Labonté A, Sanchez E, Duclos C, Mohammediyan B, Ashton NJ, Zetterberg H, Blennow K, Breitner JCS, Villeneuve S, Poirier J; PREVENT‐AD Research Group.
  Day-to-day sleep variability with Alzheimer’s biomarkers in at-risk elderly.
  Alzheimers Dement. 2024 Feb 16;16(1):e12521. [full text]
• St-Onge F, Chapleau M, Breitner JCS, Villeneuve S*, Pichet Binette A*, for the Alzheimer’s Disease Neuroimaging Initiative.
  Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum.
  Brain Commun. 2024 Feb 7:fcae031. [full text]
  *These authors contributed equally.

2023

• Quesnel MJ, Labonté A, Picard C, Zetterberg H, Blennow K, Brinkmalm A, Villeneuve S, Poirier J; Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD Research Group.
  Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.
  Brain. 2023 Nov 22:awad398. Epub ahead of print. [full text]
• Ai M, Morris TP, Noriega de la Colina A, Thovinakere N, Tremblay-Mercier J, Villeneuve S, H Hillman C, Kramer AF, Geddes MR; PREVENT-AD Research Group.
  Midlife physical activity engagement is associated with later-life brain health.
  Neurobiol Aging. 2023 Nov 11;134:146-159. Epub ahead of print. [full text]
• Samson AD, Rajagopal S, Pasvanis S, Villeneuve S; PREVENT-AD Research Group; McIntosh AR, Rajah MN.
  Sex differences in longitudinal changes of episodic memory-related brain activity and cognition in cognitively unimpaired older adults with a family history of Alzheimer’s disease.
  Neuroimage Clin.. 2023 Oct 29;40:103532. Epub ahead of print. [full text]
• Parent O, Bussy A, Devenyi GA, Dai A, Costantino M, Tullo S, Salaciak A, Bedford S, Farzin S, Béland ML, Valiquette V, Villeneuve S, Poirier J, Tardif CL, Dadar M; PREVENT-AD Research Group; Chakravarty MM.
  Assessment of white matter hyperintensity severity using multimodal magnetic resonance imaging.
  Brain Commun. 2023 Oct 19;5(6):fcad279. [full text]
• St-Onge F, Javanray M, Pichet Binette A, Strikwerda-Brown C, Remz J, Spreng RN, Shafiei G, Misic B, Vachon-Presseau E, Villeneuve S.
  Functional connectome fingerprinting across the lifespan.
  Netw. Neurosci. 2023 Oct 1;7(3):1206-1227. [full text]
• Ourry V, Pichet Binette A, St-Onge F, Strikwerda-Brown C, Chagnot A, Poirier J, Breitner J, Arenaza-Urquijo EM, Rabin JS, Buckley R, Gonneaud J, Marchant NL, Villeneuve S.
  How do modifiable risk factors affect Alzheimer’s disease pathology or mitigate its effect on clinical symptom expression?
  Biol Psychiatry. 2023 Sep 7. Epub ahead of print. [abstract]
• Tanguay-Sabourin C, Fillingim M, Guglietti GV, Zare A, Parisien M, Norman J, Sweatman H, Da-Ano R, Heikkala E; PREVENT-AD Research Group; Perez J, Karppinen J, Villeneuve S, Thompson SJ, Martel MO, Roy M, Diatchenko L, Vachon-Presseau E.
  A prognostic risk score for development and spread of chronic pain.
  Nat Med. 2023 Jul;29(7):1821-1831. [full text]
• Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac PR, Gonzalez-Ortiz F, Gallego Rudolf J, Meyer PF, St-Onge F, Schöll M, Soucy JP, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; PREVENT-AD Research Group.
  Longitudinal blood biomarker trajectories in preclinical Alzheimer’s disease.
  Alzheimers Dement. 2023 Jun 9. Epub ahead of print. [full text]
• Ai M, Morris TP, Zhang J, Noriega de la Colina A, Tremblay-Mercier J, Villeneuve S, Whitfield-Gabrieli S, Kramer AF, Geddes MR; PREVENT-AD Research Group.
  Resting-state MRI functional connectivity as a neural correlate of multidomain lifestyle adherence in older adults at risk for Alzheimer’s disease.
  Sci Rep. 2023 May 9;13(1):7487. [full text]
• Veréb D, Mijalkov M, Chang YW, Canal-Garcia A, Gomez-Ruis E, Maass A, Villeneuve S, Volpe G, Pereira JB.
  Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease.
  Alzheimers Res Ther. 2023 Apr 19;15(1):82. [full text]
• Wood ME, Xiong LY, Wong YY, Buckley RF, Swardfager W, Masellis M, Lim ASP, Nichols E, Joie R, Casaletto KB, Kumar RG, Dams-O’Connor K, Palta P, George KM, Satizabal CL, Barnes LL, Schneider JA, Pichet Binette A, Villeneuve S, Pa J, Brickman AM, Black SE, Rabin JS; ADNI and PREVENT-AD Research Groups.
  Sex differences in associations between APOE ε2 and longitudinal cognitive decline.
  Alzheimers Dement. 2023 Oct;19(10):4651-4661. doi: 10.1002/alz.13036. Epub 2023 Mar 30. [full text]
• Intzandt B, Sanami S, Huck J, PREVENT-AD Research group, Villeneuve S, Bherer L, Gauthier CJ.
  Sex-specific relationships between obesity, physical activity, and gray and white matter volume in cognitively unimpaired older adults.
  GeroScience. 2023 Jun;45(3):1869-1888. Epub 2023 Feb 13. [abstract]
• Shafighi K, Villeneuve S, Rosa-Neto P, Badhwar A, Poirier J, Sharma V, Medina YI, Silveira PP, Dube L, Glahn D, Bzdok D.
  Social isolation is linked to classical risk factors of Alzheimer’s disease-related dementias.
  PLoS One. 2023 Feb 1;18(2):e0280471. [full text]

2022

• Dauar MT, Labonté A, Picard C, Miron J, Rosa-Neto P, Zetterberg H, Blennow K, Villeneuve S, Poirier J.
  Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer’s disease spectrum.
  Alzheimers Dement. 2023 Jul;19(7):2816-2830. doi: 10.1002/alz.12868. Epub 2022 Dec 30. [full text]
• Savignac C, Villeneuve S, Badhwar A, Saltoun K, Shafighi K, Zajner C, Sharma V, Gagliano Taliun SA, Farhan S, Poirier J, Bzdok D.
  APOE alleles are associated with sex-specific structural differences in brain regions affected in Alzheimer’s disease and related dementia.
  PLoS Biol. 2022 Dec 13;20(12):e3001863. [full text]
• Morrison C, Dadar M, Villeneuve S, Ducharme S, Collins DL.
  White matter hyperintensity load varies depending on subjective cognitive decline criteria.
  GeroScience. 2023 Feb;45(1):17-28. Epub 2022 Nov 19. [abstract]
• Ozlen H, Pichet Binette A, Köbe T, Meyer PF, Gonneaud J, St-Onge F, Provost K, Soucy JP, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative, the Harvard Aging Brain Study, the PREVENT-AD Research Group.
  Spatial extent of amyloid-β levels and associations with tau-PET and cognition.
  JAMA Neurol. 2022 Oct 1;79(10):1025-1035. [abstract]
• Strikwerda-Brown C, Hobbs DA*, Gonneaud J*, St-Onge F, Pichet Binette A, Ozlen H, Provost K, Soucy JP, Buckley RF, Benzinger TLS, Morris JC, Villemagne VL, Doré V, Sperling RA, Johnson KA, Rowe CC, Gordon BA, Poirier J, Breitner JCS, Villeneuve S; PREVENT-AD, HABS, and AIBL Research Groups.
  Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment.
  JAMA Neurol. 2022 Jul 30. [full text]
  *These authors contributed equally.
• Morrison C, Dadar M, Villeneuve S, Collins DL.
  White matter lesions may be an early marker for age-related cognitive decline.
  Neuroimage Clin. 2022 Jun 22. [full text]
• Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R.
  Tau PET imaging in neurodegenerative disorders.
  J Nucl Med. 2022 Jun 1. [full text]
• Bethlehem RAI, Seidlitz J., …, Villeneuve S. et al.
  Brain charts for the human lifespan.
  Nature. 2022 April 6. [full text]
• Jansen WJ, Janssen O, Tijms BM, Vos SJ, Ossenkoppele R, Visser PJ, … & Scheltens P. (2022).
  Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum.
  JAMA Neurol. 2022 Jan 31. [full text]
• Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, Vanmechelen E, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
  Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.
  Ann Neurol. 2022 Jan 27. [full text]
• Strikwerda-Brown C, Ozlen H, Pichet Binette A, Chapleau M, Marchant NL, Breitner JC, Villeneuve S, PREVENT-AD Research Group.
  Trait mindfulness is associated with less amyloid, tau, and cognitive decline in individuals at risk for Alzheimer’s disease.
  Biol Psychiatry Glob Open Sci. 2022 Jan 17. [full text]

2021

• Morrison C, Dadar M, Shafiee N, Villeneuve S, Collins DL; for Alzheimer’s Disease Neuroimaging Initiative.
  Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline.
  Neuroimage Clin. 2021 Dec 21;33:102923. [full text]
• Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Pichet Binette A, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L; Alzheimer’s Disease Neuroimaging Initiative; FACEHBI study group; PREVENT-AD Research Group, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ.
  Characteristics of subjective cognitive decline associated with amyloid positivity.
  Alzheimers Dement. 2021 Dec 8. [full text]
• Nilsson NIV, Picard C, Labonté A, Köbe T, Meyer PF, Villeneuve S, Auld D, Poirier J, PREVENT-AD Research Group, Alzheimer’s Disease Neuroimaging Initiative.
  Association of a total cholesterol polygenic score with cholesterol levels and pathological biomarkers across the Alzheimer’s disease spectrum.
  Genes. 2021 Nov 17. [full text]
• Picard C, Nilsson N, Labonté A, Auld D, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative, Ashton NJ, Zetterberg H, Blennow K, Breitner JCB, Villeneuve S, Poirier J; PREVENT-AD Research Group.
  Apolipoprotein B is a novel marker for early tau pathology in Alzheimer’s disease.
  Alzheimers Dement. 2021 Sep 29. [full text]
• Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Presseau E, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN) Study Group; PREVENT-AD Research Group.
  Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease.
  Nat Commun. 2021 Sep 9;12(1):5346. [full text]
• Tremblay-Mercier J, Madjar C, Das S, Pichet Binette A, Dyke SOM, Étienne P, Lafaille-Magnan ME, Remz J, Bellec P, Collins DL, Rajah MN, Bohbot V, Leoutsakos JM, Iturria-Medina Y, Kat J, Hoge RD, Gauthier S, Tardif CL, Chakravarty M, Poline JB, Rosa-Neto P, Evans AC, Villeneuve S, Poirier J, Breitner JCS; PREVENT-AD Research Group.
  Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease.
  Neuroimage Clin. 2021;31:102733. [full text]
• Pichet Binette A, Theaud G, Rheault F, Roy M, Collins DL, Levin J, Mori H, Lee JH, Farlow MR, Schofield P, Chhatwal JP, Masters CL, Benzinger T, Morris J, Bateman R, Breitner JC, Poirier J, Gonneaud J, Descoteaux M, Villeneuve S; DIAN Study Group; PREVENT-AD Research Group.
  Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease.
  Elife. 2021 May 13;10:e62929. [full text]
• Köbe T, Pichet Binette A, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; for the PREVENT-AD Research Group.
  Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer’s disease: Vascular risk factors and functional connectivity changes.
  NeuroImage. 2021;231:117832. [full text]
• Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O.
  The impact of demographic, clinical, genetic, and imaging variables on tau PET status.
  Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2245-2258. [full text]

2020

• Gonneaud J, Bedetti C, Pichet Binette A, Benzinger TLS, Morris JC, Bateman RJ, Poirier J, Breitner JCS, Villeneuve S; DIAN Study Group and the PREVENT-AD Research Group.
  Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease.
  Neurology. 2020;95(11):e1554-e1564. [abstract]
• Marchant NL, Lovland LR, Jones R, Pichet Binette A, Gonneaud J, Arenaza-Urquijo EM, Chételat G, Villeneuve S; PREVENT-AD Research Group.
  Repetitive negative thinking is associated with amyloid, tau, and cognitive decline.
  Alzheimers Dement.. 2020;16(7):1054-1064. [full text]
• Pichet Binette A, Vachon-Presseau E, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve, S; Dominantly Inherited Alzheimer Network (DIAN) and the PREVENT-AD Research Group.
  Amyloid and tau pathology associations with personality traits, neuropsychiatric factors and cognitive lifestyle in the preclinical phases of sporadic and autosomal dominant Alzheimer’s disease.
  Biol Psychiatry. 2020;S0006-3223(20)30058-5. [abstract]
• Köbe T, Gonneaud J, Pichet Binette A, Meyer P-F, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; for the PREVENT-AD Research Group.
  Association of vascular risk factors with amyloid-β peptide and tau burdens in cognitively unimpaired individuals and its interaction with vascular medication use.
  JAMA Netw Open. 2020;3(2):e1920780. [full text]
• Meyer P-F, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S.
  Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography.
  JAMA Neurol. 2020;77(4):508-516. [full text]
• Pichet Binette A, Gonneaud J, Poirier J, Vogel JW, La Joie R, Rosa-Neto P, Collins DL, Poirier J, Breitner JCS, Villeneuve S*, Vachon-Presseau E*; Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD Research Group.
  Morphometric network differences in ageing versus Alzheimer’s disease dementia.
  Brain. 2020;143(2):635-649. [full text]
  *These authors contributed equally.
• McSweeney M*, Pichet Binette A*, Meyer P-F, Gonneaud J, Bedetti C, Ozlen H, Labonté A, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S, for the PREVENT-AD Research Group.
  Intermediate flortaucipir uptake is associated with Aβ-PET and CSF-tau in asymptomatic adults.
  Neurology. 2020;94(11):e1190-e1200. [abstract, pdf]
  *These authors contributed equally.

2019

• Villeneuve S.
  Lifespan Cognitive Reserve—A Secret to Coping With Neurodegenerative Pathology.
  JAMA Neurol. 2019; 76:1145-1146. [abstract]
• Meyer P-F, McSweeney M, Gonneaud J, Villeneuve S.
  PET amyloid imaging across the Alzheimer’s disease spectrum: From disease mechanisms to prevention.
  Prog Mol Biol Transl Sci. 2019;165:63-106. [abstract, pdf]
• DeCarli C, Villeneuve S, Maillard P, Harvey D, Singh B, Carmichael O, Fletcher E, Olichney J, Farias S, Jagust W, Reed B, Mungas D.
  Vascular burden score impacts cognition independent of amyloid PET and MRI measures of Alzheimer’s disease and vascular brain injury.
  J Alzheimers Dis. 2019;68:187-196. [abstract, pdf]
• Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O*, Ossenkoppele R*, for the Alzheimer’s Disease Neuroimaging Initiative and the Swedish BioFINDER study.
  Data-driven approaches for tau-PET biomarkers in Alzheimer’s disease.
  Hum Brain Mapp. 2019;40:638-665. [full text, pdf]

2018

• Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD Research Group.
  Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease.
  Brain. 2018;141:1871-1883. [full text, pdf]
• Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; PREVENT-AD Research Group.
  Proximity to parental symptom onset and amyloid-β burden in sporadic Alzheimer disease.
  JAMA Neurol. 2018;75:608–619. [full text, pdf]
• Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.
  Subjective cognitive decline is associated with altered default mode network connectivity in individuals with a family history of Alzheimer’s Disease.
  Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:463-472. [abstract, pdf]

2017

• Mander B, Zhu A, Lindquist J, Villeneuve S, Rao V, Lu B, Saletin J, Ancoli-Israel S, Jagust W, Walker M.
  White matter structure in older adults moderates the benefit of sleep spindles on motor memory consolidation.
  J Neurosci. 2017;37:11675-11687. [full text, pdf]
• Boudjemeline M, Hopewell R, Rochon PL, Jolly D, Hammami I, Villeneuve S, Kostikov A.
  Highly efficient solid phase-supported radiosynthesis of [¹¹ C]PiB using tC18 cartridge as a “3-in-1” production entity.
  J Labelled Comp Radiopharm. 2017;60(14):632-638. [full text, pdf]
• Villeneuve S.
  Potential utility of practice effects in preventive trials.
  The Journal of Prevention of Alzheimer’s Disease. 2017;4(3):140-142. [pdf]
• Grothe MJ, Villeneuve S, Dyrba M, Bartrés-Faz D, Wirth M; Alzheimer’s Disease Neuroimaging Initiative.
  Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load.
  Neurology. 2017;88:569-576. [full text, pdf]
• Seo SW*, Ayakta N*, Grinberg LT, Villeneuve S, Lehmann M, Reed B, DeCarli C, Miller BL, Rosen HJ, Boxer AL, O’Neil JP, Jin LW, Seeley WW, Jagust WJ, Rabinovici GD.
  Regional correlations between [¹¹C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.
  Neuroimage Clin.. 2017;13:130-137. [full text, pdf]
• [preprint] Orban P, Tam A, Urchs S, Savard M, Madjar C, Badhwar A, Dansereau C, Vogel JW, Shmuel A, Dagher A, Villeneuve S, Poirier J, Rosa-Neto P, Breitner J, Bellec P, for the Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD program.
  Subtypes of functional brain connectivity as early markers of neurodegeneration in Alzheimer’s disease.
  bioRxiv 195164. 2017. [full text]

2016

• Villeneuve S.
  Cause of suspected non-Alzheimer disease pathophysiology: If not tau pathology, then what?
  JAMA Neurol. 2016;73(10):1177-1179. [abstract, pdf]
• Fletcher E, Villeneuve S, Maillard P, Harvey D, Reed B, Jagust W, DeCarli C.
  β-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals.
  Neurobiol Aging. 2016;40:173-80. [abstract, pdf]

2015

• Villeneuve S, Brisson D, & Gaudet D.
  Influence of abdominal obesity on the lipid-lipoprotein profile in apoprotein E2/4 carriers: The effect of an apparent duality.
  Journal of Lipids. 2015;2015:742408. [full text, pdf]
• Villeneuve S*, Rabinovici G*, Cohn-Sheehy B, Madison C, Ayakta N, Ghosh PM, Madison C, La Joie R, Arthur-Bentil SK, Vogel J, Marks S, Lehmann M, Rosen H, Reed B, Olichney J, DeCarli C, Miller BL, Borys E, Grinberg LT, Jin LW, Seeley WW & Jagust W.
  Existing PIB thresholds are too high: Statistical and pathological examination.
  Brain. 2015;138:2020-2033. [full text, pdf]
  *These authors contributed equally.
• Villeneuve S, Wirth M & La Joie R.
  Are AD-typical regions the convergence point of multiple pathologies?
  Front Aging Neurosci. 2015;7:42. [full text, pdf]
• Villeneuve S & Jagust W.
  Imaging vascular disease and amyloid in the aging brain: Implications for treatment.
  J Prev Alz Dis. 2015;2:64-70. [abstract, pdf]

2014

• Villeneuve S, Reed B, Madison C, Wirth M, Kriger S, Marchant N, Mack W, Sanossian N, DeCarli C, Chui H, Weiner M & Jagust W.
  Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions.
  Neurology. 2014;83:1-8. [abstract, pdf]
• Villeneuve S, Brisson D, Marchant N & Gaudet D.
  The potential application of Apolipoprotein E in personalized medicine.
  Front Aging Neurosci. 2014;6:154. [full text, pdf]
• Wirth M, Villeneuve S, La Joie R, Marks S. & Jagust W.
  Gene–Environment interactions: Lifetime cognitive activity, APOE genotype, and beta-amyloid burden.
  J Neurosci. 2014;34:8612-8617. [full text, pdf]
• Wirth M, Haase C, Villeneuve S, Vogel J & Jagust W.
  Neuroprotective Pathways: Lifestyle activity, brain pathology and cognition in cognitively normal older adults.
  Neurobiol Aging. 2014;35:1873-1882. [abstract, pdf]
• Villeneuve S, Reed BR, Wirth M, Haase CM, Madison CM, Ayakta N, Mack W, Mungas D, Chui HC, DeCarli C, Weiner M & Jagust W.
  Cortical thickness mediates the impact of β-amyloid on episodic memory.
  Neurology. 2014;82:761-762. [abstract, pdf]
• Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W.
  Associations between serum cholesterol levels and cerebral amyloidosis.
  JAMA Neurol. 2014;71:195-200. [full text, pdf]

2013

• Wirth M, Villeneuve S, Madisona C, Oh H, Rabinovici G & Jagust W.
  Associations between Alzheimer’s disease biomarkers, neurodegeneration, and cognition in normal older people.
  JAMA Neurol. 2013;70:1512-1519. [abstract, pdf]
• Peters S, Villeneuve S & Belleville S.
  Predicting progression to dementia in elderly subjects with mild cognitive impairment using both cognitive and neuroimaging predictors.
  J Alzheimer Dis. 2013;38:307-318. [abstract, pdf]
• Chao LL, DeCarli C, Kriger S, Truran D, Zhang Y, Laxamana J, Villeneuve S, Jagust WJ, Sanossian N, Mack W, Chui HC & Weiner MW.
  Associations between white matter hyperintensities and β amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI.
  PLOSone. 2013;8:e65175. [abstract, pdf]
• Villeneuve S, Pepin V, Gosselin N, Gagnon K & Gagnon J-F.
  Response to: Influence of OSA on cognitive impairment in patients with COPD.
  CHEST. 2013;143:1512-1513. [abstract, pdf]
• Oh H, Madison C, Villeneuve S, Markley C & Jagust W.
  Association of gray matter atrophy with age, β-amyloid, and cognition in aging.
  Cerebral Cortex. 2014;24(6):1609-18. Epub ahead of print 2013. [abstract, pdf]

2012

• Villeneuve S, Pépin V, Rahayel S, Bertrand J-A, Delorimier M, Desjardins C, Rizk A, Parenteau S, Beaucage F, Joncas S, Monchi O & Gagnon J-F.
  Mild cognitive impairment in moderate to severe chronic obstructive pulmonary disease.
  CHEST. 2012; 142:1516-1523. [abstract, pdf]
• Villeneuve S & Belleville S.
  The nature of memory failure in mild cognitive impairment: examining association with neurobiological markers and effect of progression.
  Neurobiol Aging. 2012; 33:1967-1978. [abstract, pdf]

2011

• Villeneuve S, Massoud F, Bocti C, Gauthier S & Belleville S.
  The nature of episodic memory deficits in MCI with and without vascular burden.
  Neuropsychologia. 2011; 49:3027-3035. [abstract, pdf]
• Hudon C, Villeneuve S & Belleville S.
  The effect of semantic orientation at encoding on free recall performance in amnestic mild cognitive impairment and probable Alzheimer’s disease.
  J Clin Exp Neuropsychol. 2011; 33:631-638. [abstract, pdf]
• Villeneuve S, Rodrigues-Brazète J, Joncas S, Postuma RB, Latreille V, Gagnon JF.
  Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson’s disease and REM sleep behavior disorder.
  Dement Geriatr Cogn Disord. 2011; 31:210-217. [abstract, pdf]
• Ouellet C, Melançon L & Villeneuve S.
  Symptômes neuropsychiatriques et interventions cognitives chez les personnes avec trouble cognitif léger.
  Revue québ. Psychol. 2011; 32:35-56. [abstract]

2010 and earlier

• Villeneuve S & Belleville S.
  Cognitive reserve and neuronal changes associated with aging.
  Psychol Neuropsychiatr du Vieil., 2010; 8:133-140. [abstract, pdf]
• Belleville S, Villeneuve S, Peters F & Protat S.
  Vascular burden, cognition and aging.
  Revue de neuropsychologie, 2010; 2:1-8. [abstract, pdf]
• Villeneuve S, Belleville S, Massoud F, Bocti C & Gauthier S.
  Impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment.
  Dement Geriatr Cogn Disord. 2009; 27:375-381. [abstract, pdf]
• [book] Belleville S & Villeneuve S.
  Aspects neuropsychologiques de la démence vasculaire. Actualités sur les démences : Aspects Cliniques et Neuropsychologiques.
  Édition Solal : mai 2006. [book]

_________________________________________________________________

DISCLAIMER: The documents distributed here have been provided as a means to ensure timely dissemination of scholarly and technical work on a noncommercial basis. Copyright and all rights therein are maintained by the authors or by other copyright holders, notwithstanding that they have offered their works here electronically. It is understood that all persons copying this information will adhere to the terms and constraints invoked by each author’s copyright and or other publishers (as appropriate). These works may not be reposted without the explicit permission of the copyright holder.

_________________________________________________________________